Trial reportBMC pulmonary medicine2014
Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis.
Trial report in BMC pulmonary medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01983774 (Effect of Proton Pump Inhibitors on CF Exacerbations), which is not on this map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Proton Pump Inhibitors on CF Exacerbations
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Guidelines on diagnosis and management of gastroesophageal reflux disease in infants, children and adolescents: a joint consensus from Italian pediatric societies (SIP and SIGENP) -Part II: management.Italian journal of pediatrics · 2026Guideline
- Drug therapies for reducing gastric acidity in people with cystic fibrosis.The Cochrane database of systematic reviews · 2021Pooled it
- Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.The Cochrane database of systematic reviews · 2020Pooled it
- Drug therapies for reducing gastric acidity in people with cystic fibrosis.The Cochrane database of systematic reviews · 2016Pooled it
- Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis.Journal of pediatric gastroenterology and nutrition · 2024Article
- Diagnosis and Management of Gastrointestinal Manifestations in Children with Cystic Fibrosis.Diagnostics (Basel, Switzerland) · 2024Review
- Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023Article
- Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management.Nutrients · 2022Review
- Use of proton pump inhibitors is associated with lower hemoglobin levels in people with cystic fibrosis.Pediatric pulmonology · 2021Article
- Luminal Gastrointestinal Manifestations of Cystic Fibrosis.Current gastroenterology reports · 2021Review
- Focus on gastroesophageal reflux disease in patients with cystic fibrosis.World journal of gastroenterology · 2020Review
- Current therapies for gastro-oesophageal reflux in the setting of chronic lung disease: state of the art review.ERJ open research · 2020Review
- Pulmonary aspiration in preschool children with cystic fibrosis.Respiratory research · 2018Article
- Proton Pump Inhibitor Use Is Associated With an Increased Frequency of Hospitalization in Patients With Cystic Fibrosis.Gastroenterology research · 2017Article
- A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.Advances in therapy · 2017Review
- Beyond pancreatic insufficiency and liver disease in cystic fibrosis.European journal of pediatrics · 2016Review
- Microbiological profiles of sputum and gastric juice aspirates in Cystic Fibrosis patients.Scientific reports · 2016Article
- Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology.American journal of physiology. Gastrointestinal and liver physiology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundGastro esophageal reflux (GER) is common in cystic fibrosis (CF) and may contribute to lung disease. Approximately 50% of patients with cystic fibrosis are being treated with proton pump inhibitors (PPIs).
methodsIn a randomized controlled study in adults, we compared treatment with esomeprazole 40 mg twice daily versus placebo in patients with CF and frequent respiratory exacerbations over a thirty-six week treatment period to determine effect on time to first exacerbation and other health related outcomes.
results17 patients without symptoms of GER were randomized and 15 completed the study. 13 subjects underwent 24 hour ambulatory pH probe monitoring; 62% had pH probe evidence of GER. Forty one percent of subjects had a pulmonary exacerbation during the study. There was no significant difference in time to first pulmonary exacerbation (log rank test p = 0.3169). Five of nine subjects in the esomeprazole group compared with 2 of eight subjects in the placebo group experienced exacerbations (esomeprazole vs. placebo: odds ratio = 3.455, 95% CI = (0.337, 54.294), Fisher's exact test: p = 0.334). There was no change in Forced Expiratory Volume in one second, Gastroesophageal Symptom Assessment Score or CF Quality of Life score between the two treatment groups.
conclusionsThere was a trend to earlier exacerbation and more frequent exacerbations in subjects randomized to esomeprazole compared with placebo. The effect of proton pump inhibitors on pulmonary exacerbations in CF warrants further investigation. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov, NCT01983774.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.